Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Chemicals In Common Consumer Products May Play A Role In Pre-Term Births
A new study of expectant mothers suggests that a group of common environmental contaminants called phthalates, which are present in many industrial and consumer products including everyday personal care items, may contribute to the country"s alarming rise in premature births.
generic viagra online
Charity Action Duchenne Combines Social Networking With E-commerce For Innovative New Website
Action Duchenne, the Duchenne Muscular Dystrophy Charity, has launched its new website which combines the best in Web 2.0 technologies including social networking, wikipedia, blogging and micro-blogging. The new site Action Duchenne also enables the charity to take donations from registered members and the general public. Users may also create their own sponsorable events with donations going directly to Action Duchenne.
News of the day
Management Change At Actelion - Isaac Kobrin To Take Newly Created Position Of Chief Medical Officer
Actelion Ltd (SIX: ATLN) announced the creation of the position of Chief Medical Officer (CMO). This change was initiated to fulfill the needs of a fast growing organization, which is developing products rapidly and managing a growing portfolio. Effective 1 July 2009, the current Head of Clinical Development, Isaac Kobrin will move into this position. He will continue to be a member of Actelion"s Executive Committee (AEC).
Oncology

Is It Legitimate To Stop Clinical Trials Early On Account Of Their "Opportunity Costs"?

A provocative debate in this week"s PLoS Medicine examines whether it would be legitimate to stop a clinical trial of a global health tool early in order to reallocate the res to testing newer products. After the failure of three large clinical trials of vaginal microbicide candidates (chemical agents aimed at preventing HIV infection), a 2007 editorial in Nature stated that the microbicide field "requires a mechanism to help it make rational choices about the best candidates to move through trials." In the PLoS Medicine debate, James Lavery (University of Toronto, Canada) and colleagues propose one such mechanism, based on stopping trials early for "opportunity costs." They argue that microbicide trial sites could have been saturated with trials of scientifically less advanced products, while newer, and potentially more promising, products were being developed. They propose a mechanism to reallocate res invested in existing trials of older products that might be better invested in more scientifically advanced products that are awaiting clinical testing. But countering Lavery and colleagues" proposal, David Buchanan (University of Massachusetts, Amherst, USA) argues that stopping trials early for such opportunity costs would pose insurmountable practical barriers, and would risk causing harm to the participants in the trial that was stopped. Funding: James Lavery and colleagues" article was funded by a grant from the Bill & Melinda Gates Foundation (BMGF) to Drs. Singer and Lavery. Lavery and colleagues presented an earlier version of their ideas at the BMGF, and feedback was taken into consideration in revisions of their paper. Peter Singer is also Sun Life Financial Chair in Bioethics at University of Toronto. The funders had no role in the decision to submit the manuscript or in its preparation. David Buchanan received no specific funding for his article. Citation: "In Global Health Research, Is It Legitimate To Stop Clinical Trials Early on Account of Their Opportunity Costs?" Lavery JV, Ridzon R, Singh JA, Slutsky AS, Anisko JJ, et al. (2009) PLoS Med 6(6): e1000071. doi:10.1371/journal.pmed.1000071 Plos Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009